Johnson & Johnson

1Q Revenues: $15 billion (+16%)

1Q Earnings: $2.6 billion (-22%)

Comments: Worldwide Pharmaceutical sales were $6.2 billion in the quarter, up 11%. Sales growth reflects the strong performance of Topamax, Levaquin, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings in the quarter reflect an in-process R&D charge of $807 million associated with the acquisition of Conor Medsystems, Inc.

News from our sister sites